MedTrace Logo

Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer

NCT01940276 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-12-09

Study results available
· View outcomes & findings →

Summary

The primary goal is to prospectively estimate the median radiographic PFS of African American and Caucasian men with mCRPC to abiraterone acetate and prednisone.

Conditions

Interventions

DRUG

Abiraterone acetate

DRUG

Prednisone

Sponsors & Collaborators

Principal Investigators

  • Daniel George, MD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2019-10-08
Completion
2019-10-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01940276 on ClinicalTrials.gov